Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M

▤ Summary

Innocan Pharma reported first-quarter 2026 results and said revenue rose 29.7% quarter over quarter to US$6.47 million. The company highlighted continued momentum in its pharmaceutical and consumer wellness segments, along with high gross margins of 91.1%. It also emphasized progress around its LPT-CBD drug delivery platform, including a 505(b)(2) regulatory path and animal health catalysts. The company said it will defer its planned U.S. IPO and focus on scaling core operations in its current markets.

▦ Linked Companies